Market Intelligence, Clinical Progress, and High-Purity Reagents for Metalloproteinase-Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADAM28 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ADAM28 ECD-Fc Fusion Protein Metalloproteinase & Disintegrin domains. HEK293 Expressed (Native Glycosylation). High Purity (>95% by SDS-PAGE). Endotoxin <1EU/µg. Sequence Verified. |
View ADAM28 Products |
| Gene Delivery | ADAM28 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Suitable for shedding assays and internalization studies. |
View ADAM28 Products |
| Benchmark Ab | Anti-ADAM28 (Research Reference) Recombinant rabbit monoclonal positive control. Sequence Verified. Suitable for ELISA/Flow Cytometry. |
View ADAM28 Products |
| Validator | ADAM28 siRNA Set Three pre-validated sequences for knockdown verification. Endotoxin-free. |
View ADAM28 Products |
| Counter-Screen A | ADAM17 (TACE) Critical off-target metalloprotease for selectivity profiling. ECD-Fc Protein available. |
View ADAM17 Products |
| Counter-Screen B | ADAM10 Alpha-secretase activity control; also syndecan/Notch sheddase. Structurally homologous. ECD-Fc Protein available. |
View ADAM10 Products |
| Related Target A | CD44 Key downstream substrate in tumor metastasis signaling. |
View CD44 Products |
| Related Target B | IGFBP3 Cleavage target mediating cancer cell survival and proliferation. |
View IGFBP3 Products |
| Related Target C | ITGB1 (Integrin beta 1) Physical interactor via ADAM28 disintegrin domain; pathway cross-talk. |
View ITGB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity vs. ADAM17/TACE & ADAM10 (Safety Toxicity) | Human ADAM17 & ADAM10 Ortholog Proteins available with >95% purity. Strictly verified by Mass Spectrometry for counter-screening panels. |
| Metalloproteinase Activity Conformation | HEK293 Expression system ensures correct disulfide bond formation and cysteine-rich domain folding. Theoretical MW confirmed by reducing/non-reducing SDS-PAGE. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ADAM28 ECD-Fc proteins available. Sequence alignment >85% identity verified prior to production. |
| Cell-surface Internalization & Shedding Kinetics | Full-length ADAM28 lentivirus for stable transfection; preserves native membrane topology for flow cytometry and internalization assays. |
| Disintegrin Domain Off-target Integrin Binding | High-purity domain truncation variants (Metalloprotease-only / Disintegrin-only) for epitope mapping and mechanism deconvolution. |
| False Positives in Binding Assays | Validated siRNA included for specificity checks. Catalytic mutant (E→A) protein available for non-enzymatic binding studies. |
Live ADAM28 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADAM28 therapeutics is intensifying. Overexpressed in breast, non-small cell lung (NSCLC), bladder, and prostate carcinomas, ADAM28 serves as a pivotal node in tumor metastasis and proliferation. Major players are shifting focus from broad-spectrum metalloprotease inhibitors to highly selective biologics, with first-generation ADC and antibody-based approaches entering preclinical validation. ADAM28 also represents an emerging frontier in inflammatory cell trafficking and tumor microenvironment remodeling. The next wave of R&D is targeting substrate-specific inhibition (e.g., IGFBP-3 shedding blockade) and selectivity engineering against closely related ADAM family members and disintegrin-domain-mediated off-target interactions, while avoiding ADAM17-mediated toxicity.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging Biotech, Oncology Focused Labs, Academic Spin-offs | Solid Tumors (NSCLC, Breast, Prostate) | Internalization Assay (Need high-purity ECD-Fc with native conformation; lentivirus stable cell line) |
| Monoclonal Antibody | Early Discovery Programs, Translational Oncology Labs | Inflammation, Metastatic Carcinomas | Selectivity Profiling (Need ADAM17/ADAM10 homolog proteins to avoid off-target; native glycosylation) |
| Small Molecule / Peptide Inhibitor | Structure-Based Drug Design Groups, Specialty Pharma | Refractory Solid Tumors | Catalytic Activity Assay (Need properly folded zinc-binding domain; mutant vs WT proteins) |
| Bispecific | Immuno-oncology Platforms | Tumor Microenvironment | Heterodimer binding validation (Need cross-reactive cyno/mouse ortholog proteins) |